血液瘤之王“空白的七年”

Ofweek维科网
01 Nov 2024

本文系基于公开资料撰写,仅作为信息交流之用,不构成任何投资建议。凭借伊布替尼(Imbruvica)和维奈克拉(Venclexta)两大爆款产品,艾伯维成为全球名副其实的“血液瘤之王”。可在绚丽的光环背后,艾伯维却出现长达七年的血液瘤产品空窗期,第三款血液瘤产品Epkinly在2023年5月才姗姗来迟,此时距维奈克拉上市已经有七年之久。世人皆知艾伯维正处于“后修美乐”时代,正在极力寻找新的业绩增长点...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10